Biohit (BIOBV.HE) Stock Analysis & AI Equity Report

Biotechnology EUR Explore free reports

Biohit (BIOBV.HE) overview

Biohit (BIOBV.HE) stock analysis and AI equity research. For the latest completed financial year, 2025, Biohit reported revenue of EUR 15.7m and operating profit of EUR 3.2m; the year-end share price was 3.69 EUR and market capitalisation was EUR 56.1m. Biohit is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Biohit's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueEUR 14.9mFY 2025
Share price3.69 EURFY 2025 year end
RevenueEUR 15.7mFY 2025
Operating profitEUR 3.2mFY 2025
Net earningsEUR 2.7mFY 2025
Market capitalisationEUR 56.1mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About Biohit

Biohit Oyj is a Finnish biotechnology company focused on developing, manufacturing and marketing diagnostic products and analysis systems for gastrointestinal diseases, along with health-promoting products. Its portfolio includes the GastroPanel® diagnostic test, Acetium® products that bind acetaldehyde, and laboratory tests and instruments. The company sells through subsidiaries and a global network of distributors and partners.

Generate the Biohit report

Biohit is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Biohit and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Biohit

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.